Synthetic T Cell Antigen Receptor (STAR) Design and Construction Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Chimeric antigen receptor (CAR) T cell therapy has demonstrated high response rates in patients with B-cell malignancies, but remission durability and safety still need to be improved. Creative Biolabs has developed a new type of double-chain chimeric receptor synthetic T cell antigen receptor (STAR). Unlike traditional CARs, STAR has an innovative and patented antigen receptor complex structure. Data have demonstrated that STAR-T products have the advantages of better therapeutic effects but fewer side effects. Moreover, the unique design can be easily developed into multi-target varieties, which effectively improves the survival time of T cells in vivo and reduces the exhaustion of T cells, thereby preventing target escape and tumor recurrence.

Challenges in the Field

Chimeric antigen receptor (CAR) T cell therapy has produced encouraging clinical results, proving their therapeutic potential in mitigating tumour development. However, CAR-T cells express surface receptors that specifically target the surface antigens expressed by cancer cells, which severely limits the development of CAR-T cells in many tumor types. In addition, the targeted surface protein can also be expressed on normal cells, leading to CAR-T-mediated non-cancer killing and potentially life-threatening side effects related to the intensity of the subsequent immune response. To solve the problem of the scope and selectivity of CAR-T, researchers are turning to a method of engineering T cells based on the T cell receptor (TCR-T). TCR selectively recognize target cells comes from its unique ability to recognize cell surface "antigens". These antigens can be used as selective identifiers for malignant cells, and more and more tumor-related antigens have been identified so that effective and selective TCR-Ts can be designed for cancer. Various TCR-T products that have been developed have shown safe and positive therapeutic effects in clinical studies.

STAR-T cell therapy combines the advantages of CAR-T and TCR-T therapy, fusing two scFv antibodies to the α chain and β chain of TCR respectively. Therefore, STAR-T scFv is designed to target the surface antigen of cancer cells (similar to CAR), but at the same time retain the natural activation signal of TCR (similar to TCR).

Features of STAR-T

Innovated structure with series of PCT patents
Functioned better with improved T cell expansion and reduced T cell depletion
Easily derived to multi-target forms for preventing tumor recurrence due to target escape
Infiltrated into solid tumor more efficiently
Clinical safety and efficacy confirmed

STAR Design and Construction Services at Creative Biolabs

Empowered by the advanced Smart™ CAR development platform, Creative Biolabs is capable of providing STAR CAR design and construction services. In addition to designing and cloning the classic CARs (1rd-4rd), we also provide multiple next-generation CAR vector products, such as synnotch CAR，universal CAR, overexpressed CAR, and switch CAR, etc. As the leading cell therapeutics biotech, Creative Biolabs masters the most advanced technology and has a very rich extensive experience and thus can ensure the best quality of CAR vector products.

For more detailed information, please feel free to contact us or directly sent us an inquiry.